Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancers With HER2 Expression”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT00440622
What this trial is testing

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 90
Post-approval studies (Phase 4)UnknownNCT05861635
What this trial is testing

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Who this might be right for
Breast CancerNeoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 42
Testing effectiveness (Phase 2)Ended earlyNCT00351858
What this trial is testing

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsBreast Cancer
Neovii Biotech 40
Early research (Phase 1)Not Yet RecruitingNCT07436858
What this trial is testing

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)HER2 ExpressionHER2 Gene Mutation
The Netherlands Cancer Institute 20
Not applicableLooking for participantsNCT07030569
What this trial is testing

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Who this might be right for
RadiomicRadiomicsBreast Cancer Metastatic+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 500
Not applicableStudy completedNCT01081600
What this trial is testing

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

Who this might be right for
Breast Cancer
University Medical Center Groningen 7
Testing effectiveness (Phase 2)Study completedNCT03321981
What this trial is testing

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Who this might be right for
Breast Cancer Metastatic
Merus B.V. 105
Testing effectiveness (Phase 2)Ended earlyNCT02115048
What this trial is testing

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Who this might be right for
Breast Neoplasms
Translational Research in Oncology 44
Not applicableLooking for participantsNCT07630402
What this trial is testing

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
University of Rochester 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 59
Large-scale testing (Phase 3)Looking for participantsNCT04400695
What this trial is testing

RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 366
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Testing effectiveness (Phase 2)Looking for participantsNCT06420973
What this trial is testing

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Who this might be right for
Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute 54
Not applicableUnknownNCT04288141
What this trial is testing

Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies

Who this might be right for
HER2-positive Breast Cancer
King's College London 40
Early research (Phase 1)Ended earlyNCT02512237
What this trial is testing

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Zhejiang Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT00479674
What this trial is testing

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Duke University 41
Early research (Phase 1)Study completedNCT03255070
What this trial is testing

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Who this might be right for
Breast NeoplasmsGastric NeoplasmSolid Tumors
Ambrx, Inc. 106
Not applicableNot Yet RecruitingNCT07670182
What this trial is testing

The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

Who this might be right for
Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 100
Testing effectiveness (Phase 2)UnknownNCT06227156
What this trial is testing

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
RemeGen Co., Ltd. 40
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Next Page